However, when comparing the combined therapy (metformin 1000 mg BID + liraglutide 1.2 mg/day) with metformin alone, Salamun et al
GLP-1 receptor agonists (semaglutide, tirzepatide, and the next generation behind them) shift glucose, lipids, inflammation, kidney function, and liver enzymes
Oral administration subjects the peptide to gastric degradation, which is why most peptides cannot be taken orally
Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications

If a product claims GLP-1 effects but contains no GLP-1 compounds and uses a delivery method with no proven efficacy, the claims do not match the science
Even as caloric intake decreases, it's important to meet your daily protein needs